Basilea Pharmaceutica (XSWX:BSLN) Total Receivables: CHF61.6 Mil (As of Dec. 2025)


XSWX:BSLN Basilea Pharmaceutica Ltd XSWX:BSLN
61 GF Score
Price CHF54.30
GF Value CHF57.52
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Basilea Pharmaceutica Total Receivables?

Basilea Pharmaceutica XSWX:BSLN +2.26% 61 Total Receivables is CHF61.6 Mil as of Dec. 2025. GuruFocus rates XSWX:BSLN with a GF Score™ of 61/100 and a GF Value™ of CHF57.52 (Fairly Valued). The stock has 4 warning signs investors should review.

Basilea Pharmaceutica's Total Receivables for the quarter that ended in Dec. 2025 was CHF61.6 Mil.

Basilea Pharmaceutica Total Receivables Related Terms

Basilea Pharmaceutica Total Receivables Historical Data

* Premium members only.

The historical data trend for Basilea Pharmaceutica's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Basilea Pharmaceutica Total Receivables Chart

Basilea Pharmaceutica Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 59.05 56.55 54.99 56.58 61.59

Basilea Pharmaceutica Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 54.99 47.58 56.58 56.04 61.59
XSWX:BSLN
61GF Score
Basilea Pharmaceutica Ltd XSWX:BSLN
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Basilea Pharmaceutica Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of CHF61.6 Mil mean?
Basilea Pharmaceutica (XSWX:BSLN) has a Total Receivables of CHF61.6 Mil as of Dec. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Basilea Pharmaceutica and its competitors.
Is Basilea Pharmaceutica's Total Receivables too high?
Basilea Pharmaceutica's current Total Receivables is CHF61.6 Mil. Overall, Basilea Pharmaceutica has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Basilea Pharmaceutica's Total Receivables compare to VRTX and REGN?
Basilea Pharmaceutica's Total Receivables of CHF61.6 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Basilea Pharmaceutica and its competitors. Basilea Pharmaceutica's current Total Receivables is CHF61.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Basilea Pharmaceutica stock overvalued right now?
Based on GuruFocus' analysis, Basilea Pharmaceutica (XSWX:BSLN) is currently considered Fairly Valued. The stock's GF Value™ is CHF57.52, compared to a current price of CHF54.30 — trading 5.6% below its estimated fair value. The current Total Receivables is CHF61.6 Mil. Basilea Pharmaceutica's overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Basilea Pharmaceutica (XSWX:BSLN), the current Total Receivables is CHF61.6 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Basilea Pharmaceutica (XSWX:BSLN) Overvalued in 2026?

Based on GuruFocus' analysis, Basilea Pharmaceutica stock appears to be undervalued. The current stock price of CHF54.30 is trading 5.6% below its estimated GF Value™ of CHF57.52. GuruFocus considers Basilea Pharmaceutica to be Fairly Valued.

Key valuation signals for XSWX:BSLN:

  • Total Receivables: CHF61.6 Mil
  • GF Value™: CHF57.52 vs. price of CHF54.30 (5.6% below fair value)
  • GF Score™: 61/100 with 4 warning signs

No single metric tells the full story. See the XSWX:BSLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Basilea Pharmaceutica Business Description

Address Hegenheimermattweg 167b, Allschwil, CHE, 4123
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.
61GF Score

Get the complete analysis for XSWX:BSLN

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF54.30
Price
CHF57.52
GF Value